scispace - formally typeset
S

Seung-Mo Hong

Researcher at University of Ulsan

Publications -  383
Citations -  21628

Seung-Mo Hong is an academic researcher from University of Ulsan. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 53, co-authored 361 publications receiving 17907 citations. Previous affiliations of Seung-Mo Hong include University of Virginia Health System & Johns Hopkins University School of Medicine.

Papers
More filters
Journal ArticleDOI

Keratosis Lichenoides Chronica: Marked Response to Calcipotriol Ointment

TL;DR: A 35‐year‐old woman with KLC is described who had the typical features of widespread violaceous, reticulate, and striae‐like erutpions with a prominent keratotic component over a nine‐year period and who responded well to treatment with calcipotriol ointment.
Journal ArticleDOI

Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth

TL;DR: The role of epigenetic mechanisms of EYA2 gene silencing in pancreatic cancers, performed in vitro and in vivo proliferation and migration assays to assess the effect of Eya2 silencing on tumor cell growth and metastasis formation, and expression analysis to identify genes transcriptionally regulated by EYA 2 were investigated.
Journal ArticleDOI

Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients

TL;DR: Portal enhancement ratio and hepatic metastases assessed on CT were common independent prognostic factors for worse recurrence-free survival and overall survival in patients with PanNENs.
Journal ArticleDOI

Pattern of extragastric recurrence and the role of abdominal computed tomography in surveillance after endoscopic resection of early gastric cancer: Korean experiences.

TL;DR: After endoscopic resection of early gastric cancer, regional lymph node recurrence is the predominant extragastric recurrence pattern, which can be detected via abdominal computed tomography and cured by rescue surgery.
Journal ArticleDOI

Clinical and prognostic significances of nuclear and cytoplasmic KIT expressions in extrahepatic bile duct carcinomas

TL;DR: Infrequent cytoplasmic KIT expression without mutation of exon 11 suggests that imatinib mesylate may not be effective for the treatment of extrahepatic bile duct carcinoma, however, immunohistochemical study for KIT may be helpful in routine pathologic examinations for evaluating better prognosis for patients with extrahePatic biles duct carcinomas.